Discover results from the ODYSSEY OUTCOMES trial conducted in post-acute coronary syndrome (ACS) patients testing

View alirocumab dose titration and the ODYSSEY OUTCOMES
treat-to-target approach

Learn about primary MACE and additional CV endpoints in the overall population

Learn about the results on MACE in high risk patients (baseline LDL-C ≥100 mg/dL)

Select ODYSSEY OUTCOMES publications

ODYSSEY OUTCOMES rationale and study design

Schwartz G, et al. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY OUTCOMES trial. Am Heart J;168(5):682–689.

See More

Total events sub-analysis

Szarek M, et al. 2019. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol;73(4):387–396.

See More

Analysis of the effect of alirocumab on mortality

Steg P, et al. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation; doi:10.1161/CIRCULATIONAHA.118.038840. [Epub ahead of print].

See More

ODYSSEY OUTCOMES primary manuscript

Schwartz G, et al. 2018. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med;379(22):2097–2107.

See More

ACS and polyvascular disease sub-analysis

Jukema J, et al. 2019. Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial. J Am Coll Cardiol; doi: 10.1016/j.jacc.2019.03.013. [Epub ahead of print].

See More

Sub-analysis of the patients with and without diabetes

Ray KK, et al, Effects of alirocumab on cardiovascular and metabolic outcomes after acute conronary syndrome in patients with and without diabetes: a prespecified anaylsis of the Odyssey Outcomes randomised controlled trial, Lancet Diabetes endocrinol 2019; 7: 618-28.

See More

    ACS=acute coronary syndrome; LDL-C low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; PCSK9=proprotein convertase subtilisin/kexin type 9.